ADME Profiling of Antibody-Drug Conjugates

Library Number:
WEBC134792878
Author(s):
Dr. Xiaogang (Sean) Han, Stephen McDonald
Content Type:
On Demand Webinar
Related Products:
 
Early Stage Development
 

ADME Profiling of Antibody-Drug Conjugates

In this webinar, Dr. Xiaogang (Sean) Han of Pfizer, Inc. and Stephen McDonald of Waters Corporation discuss the workflows that are being employed to measure and profile ADCs, and describe the tools and techniques that are being successfully deployed in this growing area.

View to Learn:

  • Steps to development of a quantitative and qualitative analytical platform for ADCs
  • Real-life examples of workflows and strategies for ADME profiling of ADCs
  • Considerations when choosing LC-MS technologies for ADC profiling

Watch the webinar below. Hosted by Bioanalysis Journal, broadcasted live May 8, 2014

Biographies:

Dr. Han is a Senior Principle Scientist at Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc. As the head of LC/MS lab, he is responsible for the bioanalytical and ADME support for ADC portfolio of Pfizer Oncology research unit.  Prior to this, he worked at PKDM, Amgen for four years. Since his PhD training at Ecole Polytechnique, France, in biophysics, he worked in analytical and ADME area for more than 12 years.

Stephen McDonald is a Senior Manager of Pharmaceutical Business Operations of Waters Corporation. Stephen is responsible for Waters business operations in DMPK, working in partnership with customers to develop innovative solutions for the Early Development activities to advance the science that drives the journey of the molecule through the Pharmaceutical Process. Today Mr. McDonald is a recognized expert at Waters in the use of LC-MS for DMPK, attending and presenting at many international metings worldwide.